In the face of escalating antibiotic resistance, a groundbreaking new class of antibiotics is on the horizon thanks to Kinvard Bio, a Harvard startup determined to tackle the challenge of drug-resistant infections.These innovative compounds represent a significant leap in antibiotic discovery, offering renewed hope against diseases that have become increasingly difficult to treat.